Longeveron (LGVN) Retained Earnings (2021 - 2026)
Longeveron (LGVN) recorded quarterly Retained Earnings of -$137.0 million in Q1 2026, down 3.58% quarter-over-quarter from -$132.3 million in Q4 2025, and down 19.57% on a YoY basis from -$170.4 million in Q1 2025.
Longeveron (LGVN) Retained Earnings (2021 - 2026) Analysis & Trends
Longeveron's Retained Earnings history runs 6 years deep, the most recent figure standing at -$137.0 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 19.57% year-over-year to -$137.0 million; the TTM figure through Mar 2026 stood at -$137.0 million (down 19.57% YoY), while the FY2025 annual figure was -$132.3 million, down 20.71% from the prior year.
- Retained Earnings was -$137.0 million for Q1 2026 at Longeveron, down from -$132.3 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1000.0 in Q1 2024 to a low of -$137.0 million in Q1 2026.
- Historically, Retained Earnings has averaged -$90.2 million across 5 years, with a median of -$103.3 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings surged 100.0% in 2024, then tumbled 11461900.0% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$62.8 million in 2022, then sank by 35.38% to -$85.0 million in 2023, then dropped by 28.97% to -$109.6 million in 2024, then fell by 20.71% to -$132.3 million in 2025, then slipped by 3.58% to -$137.0 million in 2026.
- The last three Retained Earnings figures came in at -$137.0 million (Q1 2026), -$132.3 million (Q4 2025), and -$126.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | -137.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -137.05 Mn |
| Dec 31, 2025 | -132.31 Mn |
| Sep 30, 2025 | -126.87 Mn |
| Jun 30, 2025 | -119.60 Mn |
| Mar 31, 2025 | -114.62 Mn |
| Dec 31, 2024 | -109.61 Mn |
| Sep 30, 2024 | -105.53 Mn |
| Jun 30, 2024 | -101.00 Mn |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | -84.98 Mn |
| Sep 30, 2023 | -78.96 Mn |
| Jun 30, 2023 | -335,000.00 |
| Mar 31, 2023 | -89.00 Mn |
| Dec 31, 2022 | -62.77 Mn |
| Dec 31, 2021 | -43.94 Mn |